NCT04736355View on ClinicalTrials.gov

DAOIB for the Treatment of Mild Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Mild Cognitive Impairment
Interventions
DRUG

DAOIB

oral, for 24 weeks

DRUG

Placebo

oral, for 24 weeks

Trial Locations (1)

886

Chang Gung Memorial Hospital, Kaohsiung City

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT04736355 - DAOIB for the Treatment of Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter